Expression of microsomal prostaglandin E synthase-1 in the spinal cord in a transgenic mouse model of amyotrophic lateral sclerosis

Journal of Pharmacological Sciences

Volumn 118, Issue 2, 2012, Pages 225-236

  Miyagishi, Hiroko ^a   Kosuge, Yasuhiro ^a   Ishige, Kumiko ^a   Ito, Yoshihisa ^a  

^a NIHON UNIVERSITY   (Japan)

Author keywords

Amyotrophic lateral sclerosis; Microglia; Microsomal prostaglandin E synthase 1; Motor neuron

Indexed keywords

ISOMERASE; PROSTAGLANDIN E SYNTHASE 1; PROSTAGLANDIN E2; PROSTAGLANDIN E2 SYNTHASE; UNCLASSIFIED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME LOCALIZATION; GLIA CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MICROGLIA; MOTONEURON; MOUSE; MOUSE STRAIN; NERVE CELL; NEUROLOGIC DISEASE; NONHUMAN; PATHOGENESIS; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; ROTAROD TEST; SPINAL CORD; TRANSGENIC MOUSE; WESTERN BLOTTING;

EID: 84857593390     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.11221FP     Document Type: Article

References (48)

1. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59-62. (Pubitemid 23087289)
2. Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science. 1994;264:1772-1775. (Pubitemid 24227760)
3. Lampson LA, Kushner PD, Sobel RA. Major histocompatibility complex antigen expression in the affected tissues in amyotrophic lateral sclerosis. Ann Neurol. 1990;28:365-372. (Pubitemid 20292623)
4. Sasaki S, Shibata N, Komori T, Iwata M. iNOS and nitrotyrosine immunoreactivity in amyotrophic lateral sclerosis. Neurosci Lett. 2000;291:44-48. (Pubitemid 30658109)
5. Sakata D, Yao C, Narumiya S. Prostaglandin E2, an immunoactivator. J Pharmacol Sci. 2010;112:1-5.
6. 2 receptors in models of neurological disease. Prostaglandins Other Lipid Mediat. 2010; 91:104-112.
7. Narumiya S, FitzGerald GA. Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest. 2001;108: 25-30. (Pubitemid 32634917)
8. Klivenyi P, Kiaei M, Gardian G, Calingasan NY, Beal MF. Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem. 2004;88:576-582. (Pubitemid 38140202)
9. Almer G, Teismann P, Stevic Z, Halaschek-Wiener J, Deecke L, Kostic V, et al. Increased levels of the pro-inflammatory prostaglandin PGE2 in CSF from ALS patients. Neurology. 2002;58: 1277-1279. (Pubitemid 34411875)
10. Ilzecka J. Prostaglandin E2 is increased in amyotrophic lateral sclerosis patients. Acta Neurol Scand. 2003;108:125-129. (Pubitemid 36920662)
11. Jakobsson PJ, Thoren S, Morgenstern R, Samuelsson B. Identification of human prostaglandin E synthase: a microsomal, glutathione- dependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci U S A. 1999;96:7220-7225. (Pubitemid 29299642)
12. Tanikawa N, Ohmiya Y, Ohkubo H, Hashimoto K, Kangawa K, Kojima M, et al. Identification and characterization of a novel type of membrane-associated prostaglandin E synthase. Biochem Biophys Res Commun. 2002;291:884-889. (Pubitemid 34694357)
13. 2 biosynthesis. J Biol Chem. 2000;275:32775-32782.
14. Murakami M, Nakatani Y, Tanioka T, Kudo I. Prostaglandin E synthase. Prostaglandins Other Lipid Mediat. 2002;68-69: 383-399. (Pubitemid 35247409)
15. Almer G, Guegan C, Teismann P, Naini A, Rosoklija G, Hays AP, et al. Increased expression of the pro-inflammatory enzyme cyclooxygenase- 2 in amyotrophic lateral sclerosis. Ann Neurol. 2001;49:176-185. (Pubitemid 32157993)
16. Yasojima K, Tourtellotte WW, McGeer EG, McGeer PL. Marked increase in cyclooxygenase-2 in ALS spinal cord: implications for therapy. Neurology. 2001;57:952-956. (Pubitemid 32880185)
17. Drachman DB, Frank K, Dykes-Hoberg M, Teismann P, Almer G, Przedborski S, et al. Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann Neurol. 2002;52:771-778. (Pubitemid 35403187)
18. Pompl PN, Ho L, Bianchi M, McManus T, Qin W, Pasinetti GM. A therapeutic role for cyclooxygenase-2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. FASEB J. 2003; 17:725-727.
19. Kiaei M, Kipiani K, Petri S, Choi DK, Chen J, Calingasan NY, et al. Integrative role of cPLA with COX-2 and the effect of nonsteriodal anti-inflammatory drugs in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem. 2005;93:403-411. (Pubitemid 40547497)
20. de Oliveira AC, Candelario-Jalil E, Bhatia HS, Lieb K, Hull M, Fiebich BL. Regulation of prostaglandin E2 synthase expression in activated primary rat microglia: evidence for uncoupled regulation of mPGES-1 and COX-2. Glia. 2008;56:844-855.
21. Mehrotra S, Morimiya A, Agarwal B, Konger R, Badve S. Microsomal prostaglandin E2 synthase-1 in breast cancer: a potential target for therapy. J Pathol. 2006;208:356-363. (Pubitemid 43210522)
22. Tokuda E, Ono S, Ishige K, Naganuma A, Ito Y, Suzuki T. Metallothionein proteins expression, copper and zinc concentrations, and lipid peroxidation level in a rodent model for amyotrophic lateral sclerosis. Toxicology. 2007;229:33-41. (Pubitemid 44881163)
23. Tokuda E, Ono S, Ishige K, Watanabe S, Okawa E, Ito Y, et al. Ammonium tetrathiomolybdate delays onset, prolongs survival, and slows progression of disease in a mouse model for amyotrophic lateral sclerosis. Exp Neurol. 2008;213:122-128.
24. Garbuzova-Davis S, Sanberg CD, Kuzmin-Nichols N, Willing AE, Gemma C, Bickford PC, et al. Human umbilical cord blood treatment in a mouse model of ALS: optimization of cell dose. PLoS One. 2008;3:e2494.
25. Kosuge Y, Koen Y, Ishige K, Minami K, Urasawa H, Saito H, et al. S-allyl-L-cysteine selectively protects cultured rat hippocampal neurons from amyloid β-protein-and tunicamycin-induced neuronal death. Neuroscience. 2003;122:885-895. (Pubitemid 37485842)
26. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein- dye binding. Anal Biochem. 1976;72:248-254.
27. Kosuge Y, Kawaguchi M, Sawaki K, Okubo M, Shinomiya T, Sakai T. Immunohistochemical study on GABAergic system in salivary glands. Eur J Pharmacol. 2009;610:18-22.
28. Carriedo SG, Yin HZ, Weiss JH. Motor neurons are selectively vulnerable to AMPA/kainate receptor-mediated injury in vitro. J Neurosci. 1996;16:4069-4079. (Pubitemid 26192403)
29. Chaudhry UA, Zhuang H, Crain BJ, Dore S. Elevated microsomal prostaglandin-E synthase-1 in Alzheimer's disease. Alzheimers Dement. 2008;4:6-13.
30. Kihara Y, Matsushita T, Kita Y, Uematsu S, Akira S, Kira J, et al. Targeted lipidomics reveals mPGES-1-PGE2 as a therapeutic target for multiple sclerosis. Proc Natl Acad Sci U S A. 2009; 106:21807-21812.
31. Ikeda-Matsuo Y, Ota A, Fukada T, Uematsu S, Akira S, Sasaki Y. Microsomal prostaglandin E synthase-1 is a critical factor of stroke-reperfusion injury. Proc Natl Acad Sci U S A. 2006;103: 11790-11795. (Pubitemid 44182529)
32. 2 biosynthesis. Prostaglandins Other Lipid Mediat. 2009;88:73-81.
33. Lovgren AK, Kovarova M, Koller BH. cPGES/p23 is required for glucocorticoid receptor function and embryonic growth but not prostaglandin E2 synthesis. Mol Cell Biol. 2007;27:4416-4430. (Pubitemid 46906565)
34. Hall ED, Oostveen JA, Gurney ME. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia. 1998;23:249-256. (Pubitemid 28259722)
35. Tanaka K, Okada Y, Kanno T, Otomo A, Yanagisawa Y, Shouguchi-Miyata J, et al. A dopamine receptor antagonist L-745,870 suppresses microglia activation in spinal cord and mitigates the progression in ALS model mice. Exp Neurol. 2008;211:378-386.
36. Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 1996;19:312-318. (Pubitemid 26349059)
37. Liu B, Hong JS. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J Pharmacol Exp Ther. 2003;304:1-7. (Pubitemid 36008905)
38. Samad TA, Moore KA, Sapirstein A, Billet S, Allchorne A, Poole S, et al. Interleukin-1β-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature. 2001; 410:471-475. (Pubitemid 32240046)
39. Brenneis C, Coste O, Altenrath K, Angioni C, Schmidt H, Schuh CD, et al. Anti-inflammatory role of microsomal prostaglandin E synthase-1 in a model of neuroinflammation. J Biol Chem. 2011;286:2331-2342.
40. Hensley K, Floyd RA, Gordon B, Mou S, Pye QN, Stewart C, et al. Temporal patterns of cytokine and apoptosis-related gene expression in spinal cords of the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. J Neurochem. 2002;82:365-374. (Pubitemid 34774627)
41. Van Den Bosch L, Van Damme P, Bogaert E, Robberecht W. The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. Biochim Biophys Acta. 2006;1762:1068-1082.
42. 2 synthase gene. Essential role of the transcription factor Egr-1. J Biol Chem. 2002;277:28601-28608.
43. Bading H, Segal MM, Sucher NJ, Dudek H, Lipton SA, Greenberg ME. N-methyl-D-aspartate receptors are critical for mediating the effects of glutamate on intracellular calcium concentration and immediate early gene expression in cultured hippocampal neurons. Neuroscience. 1995;64:653-664.
44. Miller TM, Kaspar BK, Kops GJ, Yamanaka K, Christian LJ, Gage FH, et al. Virus-delivered small RNA silencing sustains strength in amyotrophic lateral sclerosis. Ann Neurol. 2005; 57:773-776. (Pubitemid 40628872)
45. Ralph GS, Radcliffe PA, Day DM, Carthy JM, Leroux MA, Lee DC, et al. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat Med. 2005;11:429-433. (Pubitemid 40562334)
46. Yamanaka K, Chun SJ, Boillee S, Fujimori-Tonou N, Yamashita H, Gutmann DH, et al. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci. 2008;11:251-253. (Pubitemid 351311795)
47. 2 receptors rescue motor neurons in a model of amyotrophic lateral sclerosis. Ann Neurol. 2004;56:240-248.
48. 2 EP2 receptor accelerates disease progression and inflammation in a model of amyotrophic lateral sclerosis. Ann Neurol. 2008;64:304-314.